OCS-01

Phase 3Small molecule

QQuan Dong Nguyen

OCS-01 is one of 76 small molecule programs targeting Cataract. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CataractActive, not recruiting

UveitisActive, not recruiting

CataractPhase 3

Active, not recruiting

UveitisPhase 2

Active, not recruiting

Competition

Competitive Landscape

219 competitors in Cataract

#DrugCompanyPhaseTrials

Lotemax

BBausch & Lomb Incorporated

Phase 3

7 2

Aquasol E

NNational Eye Institute (NEI)

Phase 3

—3

Dexamethasone Phosphate

EEyegate Pharmaceuticals, Inc.

Phase 3

1 4

Tetracaine Hydrochloride

BBausch Health Americas, Inc.

Phase 3

1 5

OCS-01

QQuan Dong Nguyen

Phase 3

1 6

Idose TR

GGlaukos Corporation

Phase 3

1 7

Zolymbus

AbbVie

Preclinical

—8

Neurontin

VViatris Specialty LLC

Preclinical

3 9

Kenalog

BBassett Healthcare

Preclinical

1 10

Duragesic

CCephalon

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Uveitis

NCT05608837

Clinical

Trials by Indication[1]

Cataract1 trial

A Phase 3 Study Evaluating the Efficacy and Safety of OCS-01 Eyedrops Compared to Vehicle for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery

Completed·OOculis·Phase 3·NCT05147233·241 enrolled

Uveitis1 trial

Multicenter Study on the Efficacy and Safety of OCS-01 in Subjects With Uveitis Related and Post Surgical Macular Edema

Active, not recruiting·QQuan Dong Nguyen·Phase 2·NCT05608837·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for OCS-01. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — OCS-01 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for OCS-01. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Quan Dong Nguyen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: QQuan Dong Nguyen

OCS-01

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Cataract1 trial

Uveitis1 trial

References

Drug Info

Quick Facts

Related News